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Background: Nonspecific PF4 ELISA assays lack specificity in diagnosing heparin-induced thrombocytopenia (HIT). Recently an IgG specific PF4 
assay became available with the potential to increase the specificity while maintaining the sensitivity of older PF4 ELISAs. The study objective was to 
evaluate whether an IgG specific PF4 assay would reduce the rate of laboratory diagnosed HIT. Secondary objectives were to determine if prescribing 
practices of direct thrombin inhibitors (DTIs) were impacted and consequently safety and economic outcomes.
Methods: We conducted a single center prospective cohort with historical control study that evaluated all adult patients admitted to Brigham and 
Women’s Hospital that were assessed for HIT using a PF4 ELISA antibody test from March 1, 2010 to April 6, 2011. Tests run between March 1 and 
August 31, 2010 utilized a nonspecific PF4 ELISA and those run between September 1, 2010 and April 6, 2011 utilized an IgG specific PF4 ELISA.
Results: Six hundred and seventy two patients with either a nonspecific PF4 ELISA (n = 336) or an IgG specific PF4 ELISA (n = 336) were included 
in the analysis. The percent of patients with a positive PF4 antibody test was 11.31 versus 6.85 (ARR 4.46%, RRR 39.47%, p = 0.044) in the 
nonspecific and IgG specific cohorts respectively. There was no difference in the percent of patients with a low, intermediate or high risk of HIT based 
on the 4Ts pretest clinical scoring system. Fewer patients were prescribed a DTI in the IgG specific cohort [87(25.9) vs. 65(19.4); p = 0.045] with an 
overall reduction in DTI expenditure of $84,286.41. The nonspecific and IgG specific cohorts were similar in the duration of DTI therapy (9.0 ± 9.1 
days vs. 9.2 ± 11.3 days; p = 0.89), hospital length of stay (17.9 ± 17.7 days vs. 20.6 ± 22.9 days; p = 0.089) and in-hospital mortality (23.5% vs. 
25.0%; p = 0.65).
Conclusions: The use of a PF4 ELISA specific for IgG antibodies was associated with a significant reduction in the laboratory diagnosis of HIT. The 
prescribing practices of direct thrombin inhibitors (DTIs) were also significantly altered during this time period resulting in a decreased cost of drug 
therapy. Further safety and efficacy outcomes are currently under evaluation.
